{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T12:19:32Z","timestamp":1790943572718,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"34","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.vaccine.2010.06.038","type":"journal-article","created":{"date-parts":[[2010,6,26]],"date-time":"2010-06-26T11:05:18Z","timestamp":1277550318000},"page":"5558-5564","source":"Crossref","is-referenced-by-count":22,"title":["A recombinant humanized monoclonal antibody completely protects mice against lethal challenge with Venezuelan equine encephalitis virus"],"prefix":"10.1016","volume":"28","author":[{"given":"Wei-Gang","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda L.","family":"Phelps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damon","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyn M.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart D.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda J.","family":"Gates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Phillpotts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Les P.","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2010.06.038_bib1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1146\/annurev.ento.49.061802.123422","article-title":"Venezuelan equine encephalitis","volume":"49","author":"Weaver","year":"2004","journal-title":"Annu Rev Entomol"},{"key":"10.1016\/j.vaccine.2010.06.038_bib2","series-title":"Fields virology","first-page":"937","article-title":"Alphaviruses","author":"Griffin","year":"2001"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2010.06.038_bib3","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1086\/513978","article-title":"Epidemic Venezuelan equine encephalitis in La Guajira, Colombia, 1995","volume":"175","author":"Rivas","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2010.06.038_bib4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev.micro.55.1.235","article-title":"Biological weapons\u2014a primer for microbiologists","volume":"55","author":"Hawley","year":"2001","journal-title":"Annu Rev Microbiol"},{"issue":"August (2)","key":"10.1016\/j.vaccine.2010.06.038_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0166-3542(00)00111-X","article-title":"Antibodies for the prevention and treatment of viral diseases","volume":"47","author":"Sawyer","year":"2000","journal-title":"Antiviral Res"},{"issue":"September (3)","key":"10.1016\/j.vaccine.2010.06.038_bib6","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1099\/0022-1317-44-3-725","article-title":"Biochemical and antigenic comparison of the envelope glycoproteins of Venezuelan equine encephalomyelitis virus strains","volume":"44","author":"France","year":"1979","journal-title":"J Gen Virol"},{"issue":"April (2)","key":"10.1016\/j.vaccine.2010.06.038_bib7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0042-6822(82)90346-4","article-title":"Antigenic analysis of the surface glycoproteins of a Venezuelan equine encephalomyelitis virus (TC-83) using monoclonal antibodies","volume":"118","author":"Roehrig","year":"1982","journal-title":"Virology"},{"issue":"April (2)","key":"10.1016\/j.vaccine.2010.06.038_bib8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0042-6822(85)90343-5","article-title":"The neutralization site on the E2 glycoprotein of Venezuelan equine encephalomyelitis (TC-83) virus is composed of multiple conformationally stable epitopes","volume":"142","author":"Roehrig","year":"1985","journal-title":"Virology"},{"issue":"February (11\u201312)","key":"10.1016\/j.vaccine.2010.06.038_bib9","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S0264-410X(01)00505-9","article-title":"Monoclonal antibody protects mice against infection and disease when given either before or up to 24h after airborne challenge with virulent Venezuelan equine encephalitis virus","volume":"20","author":"Phillpotts","year":"2002","journal-title":"Vaccine"},{"issue":"September (1\u20132)","key":"10.1016\/j.vaccine.2010.06.038_bib10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.virusres.2006.02.003","article-title":"Venezuelan equine encephalitis virus complex-specific monoclonal antibody provides broad protection, in murine models, against airborne challenge with viruses from serogroups I, II and III","volume":"120","author":"Phillpotts","year":"2006","journal-title":"Virus Res"},{"issue":"April (16)","key":"10.1016\/j.vaccine.2010.06.038_bib11","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1016\/j.vaccine.2007.01.034","article-title":"Humanization and mammalian expression of a murine monoclonal antibody against Venezuelan equine encephalitis virus","volume":"25","author":"Hu","year":"2007","journal-title":"Vaccine"},{"issue":"March (2)","key":"10.1016\/j.vaccine.2010.06.038_bib12","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0022-1759(85)90044-4","article-title":"Measurements of the true affinity constant in solution of antigen\u2013antibody complexes by enzyme-linked immunosorbent assay","volume":"77","author":"Friguet","year":"1985","journal-title":"J Immunol Methods"},{"issue":"6","key":"10.1016\/j.vaccine.2010.06.038_bib13","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s007050050363","article-title":"Humane endpoints are an objective measure of morbidity in Venezuelan encephalomyelitis virus infection of mice","volume":"143","author":"Wright","year":"1998","journal-title":"Arch Virol"},{"issue":"October (2)","key":"10.1016\/j.vaccine.2010.06.038_bib14","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1677\/jme.1.01578","article-title":"Manipulating sorting signals to generate co-expression of somatostatin and eGFP in the regulated secretory pathway from a monocistronic construct","volume":"33","author":"Davies","year":"2004","journal-title":"J Mol Endocrinol"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2010.06.038_bib15","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1006\/mthe.2000.0050","article-title":"IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector","volume":"1","author":"Mizuguchi","year":"2000","journal-title":"Mol Ther"},{"issue":"April","key":"10.1016\/j.vaccine.2010.06.038_bib16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1749-6632.1999.tb11271.x","article-title":"Studies on conditional gene expression in the brain","volume":"868","author":"Jerecic","year":"1999","journal-title":"Ann NY Acad Sci"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2010.06.038_bib17","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nbt1087","article-title":"Stable antibody expression at therapeutic levels using the 2A peptide","volume":"23","author":"Fang","year":"2005","journal-title":"Nat Biotechnol"},{"issue":"August (2)","key":"10.1016\/j.vaccine.2010.06.038_bib18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.pep.2007.03.007","article-title":"Expression of furin-linked Fab fragments against anthrax toxin in a single mammalian expression vector","volume":"54","author":"Reed","year":"2007","journal-title":"Protein Exp Purif"},{"issue":"May (Pt 5)","key":"10.1016\/j.vaccine.2010.06.038_bib19","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1099\/0022-1317-82-5-1013","article-title":"Analysis of the aphthovirus 2A\/2B polyprotein \u2018cleavage\u2019 mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal \u2018skip\u2019","volume":"82","author":"Donnelly","year":"2001","journal-title":"J Gen Virol"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2010.06.038_bib20","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nbt957","article-title":"Correction of multi-gene deficiency in vivo using a single \u2018self-cleaving\u2019 2A peptide-based retroviral vector","volume":"22","author":"Szymczak","year":"2004","journal-title":"Nat Biotechnol"},{"issue":"April (2)","key":"10.1016\/j.vaccine.2010.06.038_bib21","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1006\/viro.1995.1197","article-title":"Mechanism of neuroinvasion of Venezuelan equine encephalitis virus in the mouse","volume":"208","author":"Charles","year":"1995","journal-title":"Virology"},{"issue":"September (5)","key":"10.1016\/j.vaccine.2010.06.038_bib22","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/030098589102800509","article-title":"Pathogenesis of Venezuelan equine encephalitis virus infection in mice and hamsters","volume":"28","author":"Jackson","year":"1991","journal-title":"Vet Pathol"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2010.06.038_bib23","first-page":"164","article-title":"Venezuelan equine encephalitis in BALB\/c mice: kinetic analysis of central nervous system infection following aerosol or subcutaneous inoculation","volume":"120","author":"Vogel","year":"1996","journal-title":"Arch Pathol Lab Med"},{"issue":"September (2)","key":"10.1016\/j.vaccine.2010.06.038_bib24","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0165-5728(00)00290-3","article-title":"Inflammation is a component of neurodegeneration in response to Venezuelan equine encephalitis virus infection in mice","volume":"109","author":"Schoneboom","year":"2000","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.vaccine.2010.06.038_bib25","series-title":"Fields virology","first-page":"843","article-title":"Alphaviruses","author":"Johnston","year":"1995"},{"issue":"February (7\u20138)","key":"10.1016\/j.vaccine.2010.06.038_bib26","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/S0264-410X(98)00315-6","article-title":"TC-83 vaccine protects against airborne or subcutaneous challenge with heterologous mouse-virulent strains of Venezuelan equine encephalitis virus","volume":"17","author":"Phillpotts","year":"1999","journal-title":"Vaccine"},{"issue":"February (1)","key":"10.1016\/j.vaccine.2010.06.038_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1113\/jphysiol.1976.sp011267","article-title":"Review lecture. The blood\u2013brain barrier","volume":"255","author":"Davson","year":"1976","journal-title":"J Physiol"},{"issue":"January\u2013February (1)","key":"10.1016\/j.vaccine.2010.06.038_bib28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4161\/hv.4.1.4778","article-title":"Antibody gene-based prophylaxis and therapy for biodefence","volume":"4","author":"Hu","year":"2008","journal-title":"Hum Vacc"},{"issue":"September (Pt 9)","key":"10.1016\/j.vaccine.2010.06.038_bib29","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1099\/vir.0.81925-0","article-title":"A humanized murine monoclonal antibody protects mice either before or after challenge with virulent Venezuelan equine encephalomyelitis virus","volume":"87","author":"Hunt","year":"2006","journal-title":"J Gen Virol"},{"issue":"August (2)","key":"10.1016\/j.vaccine.2010.06.038_bib30","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/0042-6822(90)90533-W","article-title":"Variants of Venezuelan equine encephalitis virus that resist neutralization define a domain of the E2 glycoprotein","volume":"177","author":"Johnson","year":"1990","journal-title":"Virology"},{"issue":"July (14)","key":"10.1016\/j.vaccine.2010.06.038_bib31","doi-asserted-by":"crossref","first-page":"9062","DOI":"10.1128\/JVI.79.14.9062-9068.2005","article-title":"Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants","volume":"79","author":"Bakker","year":"2005","journal-title":"J Virol"},{"issue":"March (6)","key":"10.1016\/j.vaccine.2010.06.038_bib32","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1086\/500470","article-title":"Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin","volume":"193","author":"Goudsmit","year":"2006","journal-title":"J Infect Dis"},{"issue":"May (2)","key":"10.1016\/j.vaccine.2010.06.038_bib33","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1006\/viro.2000.0276","article-title":"Synergistic interactions of antibodies in rate of virus neutralization","volume":"270","author":"Sanna","year":"2000","journal-title":"Virology"},{"issue":"April (3)","key":"10.1016\/j.vaccine.2010.06.038_bib34","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s002510100314","article-title":"Viral escape from the neutralizing antibody response: the lymphocytic choriomeningitis virus model","volume":"53","author":"Ciurea","year":"2001","journal-title":"Immunogenetics"},{"issue":"March (6)","key":"10.1016\/j.vaccine.2010.06.038_bib35","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1073\/pnas.040558797","article-title":"Viral persistence in vivo through selection of neutralizing antibody-escape variants","volume":"97","author":"Ciurea","year":"2000","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10008492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10008492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,10]],"date-time":"2018-12-10T04:56:23Z","timestamp":1544417783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X10008492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":35,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S0264410X10008492"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2010.06.038","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}